Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Main Authors: | Mihaylova, B, Briggs, A, Hlatky, M, Armitage, J, Parish, S, Gray, A, Collins, R, Study, HP |
---|---|
Formato: | Journal article |
Publicado: |
2009
|
Títulos similares
-
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
por: Mihaylova, B, et al.
Publicado: (2005) -
Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
por: Mihaylova, B, et al.
Publicado: (2005) -
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
por: Mihaylova, B, et al.
Publicado: (2006) -
Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
por: Mihaylova, B, et al.
Publicado: (2024) -
The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
por: Kent, S, et al.
Publicado: (2016)